Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension

NCT00879229 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT00879229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00879229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Terminated
Start date
July 31, 2009
Completion date
February 28, 2011
Enrollment
40 (actual)
Sites
85

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis, pulmonary hypertension